Designing a personal experiment that could change your mind — one year on posts 61–81
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
On post #59 — agreed on the reasoning, with one qualification.
When to run an n-of-1: this design works when you want to know whether a treatment works for you, not whether it works in general. For that purpose, it is efficient.
Statistical analysis of n-of-1 data: comparing before versus after with a t-test or similar is one approach. Plotting the data visually is another. Both are valid.
Designing a personal experiment that could actually change your mind: that is the standard for an n-of-1 design. An experiment designed so that any result confirms what you already believed has not changed anything.
This follows post #63 rather than contradicting it.
Stopping rules: decide in advance when you will stop measuring (after a defined duration, after a defined number of measurements, or after a defined condition is met). Not deciding in advance means stopping when the result satisfies you, which is bias.
Collapsed as off-topic by two members at trust level 3 or above
Blinding: blinding yourself (not knowing which condition you are in) removes expectation bias. This is hard to do with these compounds (the appetite suppression is hard to miss) but partial blinding is possible (measuring something objective without knowing whether you took it today).
Washout periods: after stopping a medication, how long does it take for the effect to wash out? For compounds with a week-long half-life, roughly a month is needed to reach baseline. Using that washout period in a before-after design strengthens the inference.
Objective versus subjective measures: subjective measures (how you feel) are vulnerable to bias. Objective measures (weight, strength on a specific exercise) are less vulnerable but not immune.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Worth separating two things that post #68 runs together.
Statistical analysis of n-of-1 data: comparing before versus after with a t-test or similar is one approach. Plotting the data visually is another. Both are valid.
Confounding in personal experiments: other things change when you start a medication (season, exercise, diet, stress). Documenting those confounders helps you understand their contribution to the result.
Generalisability: a robust n-of-1 result applies to you. It does not tell you much about whether the effect generalises to others similar to you, much less to people different from you.
post #74 answers the question as asked. The question underneath it is different.
When to run an n-of-1: this design works when you want to know whether a treatment works for you, not whether it works in general. For that purpose, it is efficient.
On post #72 — agreed on the reasoning, with one qualification.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
When to run an n-of-1: this design works when you want to know whether a treatment works for you, not whether it works in general. For that purpose, it is efficient.
This topic was referenced in
- An ABAB design with a data table and honest limitations — a second datasetResearch Methods › N-of-1 designs · 118 replies
- Second pass at: Designing a personal experiment that could change your mindResearch Methods › N-of-1 designs · 44 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Washout with a one-week half-life: the arithmetic — does this still hold?
Washout with a one-week half-life: the arithmetic — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021)…
|
+41 | 45 | 12k | 1d |
|
Pre-registering a personal experiment, seriously
Pre-registering a personal experiment, seriously — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SUSTAIN 6 ( N Engl J Med , 2016) and finding the…
|
+96 | 119 | 58k | 14mo |
|
Blinding yourself: practical methods and their limits — the long version
Blinding yourself: practical methods and their limits — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024)…
|
+7 | 11 | 1.8k | 22h |
|
An ABAB design with a data table and honest limitations — a second dataset
On the subject in the title: An ABAB design with a data table and honest limitations — a second dataset Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before…
|
+106 | 118 | 25k | 4mo |
|
Why most self-reports here are not experiments, and that is fine
Why most self-reports here are not experiments, and that is fine — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…
|
2 | 46k | 11mo |
Related topics — sharing the tags effect size, data table, worked example
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Multiplicity when you track fifteen variables
Posting this under the heading it deserves: Second pass at: Multiplicity when you track fifteen variables Everything below is what sits behind that. I have seen SCALE ( N Engl J Med , 2015) cited in support…
|
2 | 12k | 18mo | |
|
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…
|
+27 | 31 | 1.2k | 22h |
|
Bioimpedance and hydration: why the number moves
Bioimpedance and hydration: why the number moves — setting out what I have, and where I think it stops being reliable. Longitudinal report with the method stated, because a number without a method is not a…
|
+62 | 70 | 13k | 23d |
|
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather…
|
2 | 31k | 13mo | |
|
What pooling buys you and what it destroys
The question in the title: What pooling buys you and what it destroys I will give what I have already checked below so nobody repeats it. Comparing SURMOUNT-2 ( Lancet , 2023) with LEADER ( N Engl J Med ,…
|
+74 | 83 | 6.6k | 8mo |